Abstract
To compare the effects of a potent rat renin inhibitor peptide (RIP) and angiotensin-converting enzyme (ACE) inhibitor on the intrarenal and plasma renin-angiotensin systems, anesthetized Sprague-Dawley rats were treated with an infusion of vehicle, ramipril or graded doses of the rat RIP (acetyl-His-Pro-Phe-Val-statine-Leu-he-NH2) for 30 min. Kidney and plasma samples were processed rapidly, and angiotensin peptides were separated by high-pressure liquid chromatography before measurement by a double-antibody radioimmunoassay. Blood pressure fell identically, by ∼15 mm Hg, after either the RIP or ACE inhibitor. Plasma Ang II was 83 ± 20 fmol/ml in vehicle-treated rats and fell to 28 ± 3 fmol/ml with ramipril (10 mg/kg), the dose-response zenith. Plasma Ang II was significantly lower, 9 ± 2 fmol/ml, with the highest RIP dose used. Control renal tissue Ang II was 183 ± 18 fmol/g, fell with ramipril to 56 ± 6 and then fell to a similar level (47 ± 10 fmol/g) after RIP. Ang I/Ang II ratios indicated the expected sharp drop in Ang I conversion after ramipril in plasma and tissue. RIP did not influence conversion rate in plasma but was associated with an unanticipated fall in Ang I conversion in renal tissue, perhaps reflecting local aspartyl protease inhibition, which contributes to normal Ang II formation. Also unanticipated was a rise in tissue Ang I concentration during RIP administration. Renin inhibition is more effective than ACE inhibition in blocking systemic Ang II formation, supporting studies suggesting that quantitatively important non-ACE-dependent pathways participate in Ang II formation.
Footnotes
-
Send reprint requests to: Norman K. Hollenberg, M.D., Ph.D., Brigham and Women’s Hospital, 15 Francis Street, Boston, MA 02115.
-
↵1 This work was supported in part by National Institutes of Health Grants T32-HL07609, NCRR GCRC M01-RR026376 and P01-AC00059916.
-
↵2 Present address: University of Manitoba, Health Sciences Centre Department of Internal Medicine, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada.
-
↵3 Present address: Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285.
- Abbreviations:
- RIP
- renin inhibitor peptide
- PRA
- plasma renin activity
- ACE
- angiotensin-converting enzyme
- Ang
- angiotensin
- MAP
- mean arterial blood pressure
- HPLC
- high-pressure liquid chromatography
- Received February 12, 1997.
- Accepted July 23, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|